Congress of Neurological Surgeons systematic review and evidence-based guidelines for the treatment of adults with progressive glioblastoma update: introduction and methods
Abstract
Introduction The management of glioblastoma at the time of progression is an important facet of all physicians involved in neuro-oncology. This is an update of the evidence-based guidelines for management of progressive glioblastoma published by the Congress of Neurological Surgeons and American Association of Neurological Surgeons in 2014.Methods The medical literature from July 1, 2012 through March 31, 2019 was searched in MEDLINE® and Embase® and the Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Registry, and Cochrane Database of Abstracts of Reviews of Effects to determine if information was available to update, modify or create new recommendations related to imaging, cytoreductive surgery, neuropathology, radiotherapy, cytotoxic chemotherapy, targeted therapy, and immunotherapy.Results The writing group utilized the information from the updated literature search to formulate recommendations that were exclusively evidence based and not founded on potentially biased consensus or expert opinion.Conclusion The series of guideline documents provides an update of the information and recommendations that could be derived in the 2014 version. It sets a benchmark as to what we really know about the management of this difficult disease. It also provides clues to key investigations that are necessary to move us toward truly effective disease control.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The largest and most significant performance improvement (33%, p < 7 × 10−60) was noted for the tumor core (TC) sub-compartment.
“Notably, the largest and most significant improvement (33%, p < 7 × 10−60) is noted for the TC sub-compartment, which is surgically actionable and not a trivial sub-compartment to delineate accurately43,44.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [44]
The citation lists haven’t been fetched yet
References 14 · Cited by 3
- Authors
- Olson, J. J.
- Affiliations
- Emory University (US)
- Corresponding author
- Olson, Jeffrey J.
- ORCID
- Olson, Jeffrey J.
- Venue
- Journal of Neuro-Oncology
- Published
- 2021-10-25
- Volume
- 158
- Issue
- 2
- Pages
- 133-137
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W3210570019
- Cited by
- 3
- References
- 14
- Citations by year
- 2024: 1 · 2022: 2
- FWCI
- 0.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuro-Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- evidence-based clinical guidelines, cytoreductive surgery, radiotherapy, cytotoxic chemotherapy, targeted therapy, immunotherapy, neuropathology, neuroimaging, adult brain tumors
- MeSH terms
- Neurosurgeons, Adult, Glioblastoma, Humans, Practice Guidelines as Topic, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review